Published in final edited form as:

Cancer Causes Control. 2014 July ; 25(7): 809–817. doi:10.1007/s10552-014-0382-6.

Associations between circulating 1,25(OH)₂D concentration and odds of metachronous colorectal adenoma

Elizabeth A. Hibler^{1,2}, Christine L. Sardo Molmenti^{2,3}, Peter Lance¹, Peter W. Jurutka⁴, and Elizabeth T. Jacobs^{1,2}

¹University of Arizona Cancer Center; Tucson, Arizona

²Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona

³Mailman School of Public Health, Columbia University, New York, New York

⁴School of Mathematical and Natural Sciences, Arizona State University, Phoenix, AZ

Abstract

Cellular-level studies demonstrate that the availability of the seco-steroid hormone 1 α ,25-dihydroxyvitamin D (1,25(OH)₂D) to colon cells promotes anti-carcinogenic activities. Although epidemiological data are relatively sparse, suggestive inverse trends have been reported between circulating 1,25(OH)₂D concentration and colorectal neoplasia. We therefore sought to evaluate the relationship between circulating 1,25(OH)₂D concentrations and odds for metachronous colorectal adenomas among 1,151 participants from a randomized trial of ursodeoxycholic acid for colorectal adenoma prevention. No relationship between 1,25(OH)₂D and overall odds for metachronous lesions was observed, with ORs (95% CIs) of 0.80 (0.60–1.07) and 0.81 (0.60–1.10) for participants in the second and third tertiles, respectively, compared to those in the lowest (p-trend=0.17). However, a statistically significant inverse association was observed between circulating 1,25(OH)₂D concentration and odds of proximal metachronous adenoma, with an OR (95% CI) of 0.71 (0.52–0.98) for individuals in the highest tertile of 1,25(OH)₂D compared to those in the lowest (p-trend = 0.04). While there was no relationship overall between 1,25(OH)₂D and metachronous distal lesions, there was a significantly reduced odds for women, but not men, in the highest 1,25(OH)₂D tertile compared to the lowest (OR=0.53; 95% CI 0.27–1.03; p-trend=0.05; p-interaction=0.08). The observed differences in associations with proximal and distal adenomas could indicate that delivery and activity of vitamin D metabolites in different anatomical sites in the colorectum varies, particularly by gender. These results identify novel associations between 1,25(OH)₂D and metachronous proximal and distal colorectal adenoma, and suggest that future studies are needed to ascertain potential mechanistic differences in 1,25(OH)₂D action in the colorectum.

Keywords

Vitamin D; colon cancer; 1,25(OH)₂D; colorectal adenoma

Corresponding Author: Elizabeth A. Hibler, University of Arizona Cancer Center, 1515 N. Campbell Ave, Tucson, AZ 85724-5024. Phone: 520-626-0015; ehilber@email.arizona.edu.

Conflict of Interest Disclosure: The authors have no conflicts to disclose.

Introduction

Colorectal cancer is the second leading cause of cancer-related deaths in the U.S. (1, 2). While colonoscopy is an effective means of detecting and removing colorectal lesions, screening rates currently fall well short of recommended coverage (3), and endoscopy appears to be more effective for lesions in the distal colorectum than for those the proximal region (4). Therefore, an understanding of risk factors for this disease, particularly those with differential effects by colorectal sub-site, remains critical. Sporadic colorectal neoplasia has been associated with a variety of lifestyle factors, including vitamin D status (5–7). Associations between low circulating 25(OH)D concentration and increased risk of colorectal adenomas and cancer are consistently observed (5, 8–11); however, epidemiological studies of the active vitamin D metabolite, 1 α ,25-dihydroxyvitamin D [1,25(OH) $_2$ D], are less common.

The hormone 1,25(OH) $_2$ D plays a central role in bone health as a component of the system regulating calcium homeostasis, and its concentration is maintained within a relatively narrow range due to this role (12, 13). For this reason, 1,25(OH) $_2$ D concentrations have rarely been studied in epidemiologic investigations, which have generally focused on 25(OH)D. However, a recent study by Skinner and Schwartz ascertained that serum calcium concentration, which also does not generally exhibit substantial variation within healthy individuals, is significantly associated with risk of fatal prostate cancer (14). Furthermore, it was recently reported that circulating 1,25(OH) $_2$ D levels are significantly inversely associated with serum fibroblast growth factor 23 (FGF23), suggesting that circulating 1,25(OH) $_2$ D concentrations may be modifiable while remaining within a physiologically functional range (15). These studies demonstrate that levels of homeostatically-controlled metabolites vary enough in circulation to justify evaluation in epidemiological studies. Further, it is possible that there may be differential effects of 1,25(OH) $_2$ D in the colorectum by factors such as gender, adenoma characteristics, or location in the colorectum.

Variation in risk of colorectal neoplasia by gender, anatomical location, or advanced histological characteristics has been reported, and may be differentially influenced by specific risk factors (6, 16, 17). The hormone 1,25(OH) $_2$ D is an example of one such risk factor, as it is not fully understood how circulating 1,25(OH) $_2$ D levels or availability of 1,25(OH) $_2$ D at the colonic epithelial cell level may vary by gender or differentially affect metachronous neoplasia by colorectal sub-site or by adenoma features. Therefore, the purpose of this study was to evaluate associations between circulating 1,25(OH) $_2$ D concentration and metachronous colorectal adenomas, while accounting for participant and adenoma characteristics that could influence these relationships.

Methods

Study population

The present study was conducted among participants of a randomized, double blind, placebo-controlled phase III trial of ursodeoxycholic acid (UDCA) for adenoma prevention conducted at the University of Arizona Cancer Center, which has been described in detail

previously (18). Briefly, eligible participants were male and female Arizona residents (n=1192) ranging in age from 40 to 80 years, and who had one or more colorectal adenomas (>3mm in diameter) removed during a colonoscopic evaluation within 6 months of entering the study. The primary study aim was to compare the effect of UDCA (8–10 mg/kg of body weight/day) versus placebo on the risk of metachronous colorectal adenoma (18). There was no evidence that UDCA treatment decreased the overall rate of metachronous adenoma in the primary analyses (18). Complete data for metachronous adenomas and circulating 1,25(OH)₂D concentration were available for 1,150 participants. The University of Arizona Human Subjects committee and local hospital committees approved the UDCA study, and written informed consent was obtained from each participant prior to study enrollment.

Dietary, sociodemographic, and medical history data were collected at baseline using self-administered questionnaires. Dietary data were obtained with the Arizona Food Frequency Questionnaire (AFFQ), a validated, 113-item, semi-quantitative, scannable instrument, with study participants asked to report their usual dietary intake during the prior year (19). A scale of seven categories ranging from >3 times/day to rarely/never was employed for most items; for beverages and commonly-consumed foods, the scale ranged from >6 times/day to rarely/never (19). Portion sizes of small, medium, or large were also recorded for each food item and total nutrients intake was calculated by multiplying the frequency of each item's consumption by the nutrient composition for each portion size (19).

Study Endpoints

For this study, metachronous colorectal adenomas were defined as adenomas detected by colonoscopy at least six months after randomization to the parent trial. In the past, these lesions have been defined as 'recurrences'; however, to account for the possibility that some of the lesions discovered at the follow-up colonoscopy may have been missed at baseline colonoscopy, the term 'metachronous' adenomas will be used herein (20). Detailed data regarding adenoma characteristics including number, size, location, and histology were obtained via medical records and pathology reports for each subject. Adenomas were classified as advanced if they had a diameter of 1 cm or more and/or tubulovillous/villous architecture (at least 25% villous) and/or the presence of high-grade dysplasia and/or cancer. Additionally, adenocarcinomas (n=12) were counted as advanced lesions. All other adenomas were considered non-advanced (<1 cm in size, tubular architecture, and no high-grade dysplasia). In subjects with more than one adenoma, size and characterization of the histologic type were based on the largest and/or most advanced adenoma.

Analysis of Vitamin D metabolite levels

Vitamin D metabolite concentrations at baseline were measured at Heartland Assays (Ames, IA). The lab utilized an ¹²⁵I-based radioimmunoassay, which is an established practice and has been described in detail previously (21). Quality assurance and control measures, including pooled sample analysis with batches of study samples for measuring analytical precision and possible laboratory shifts over time as well as duplicate testing in batches, were utilized by the laboratory. The coefficient of variation was 11.5% for 1,25(OH)₂D analysis (22) and the analyses were conducted in a blinded fashion.

Statistical Analysis

Participant characteristics were compared by tertile of 1,25(OH)₂D concentration with means and standard deviations calculated for the continuous variables, and frequencies and percentages for the categorical variables. Circulating 1,25(OH)₂D concentrations were evaluated as overall and gender-specific tertiles. Unconditional logistic regression modeling was used to evaluate the associations between 1,25(OH)₂D concentrations and metachronous colorectal adenoma characteristics. Potential confounding was assessed for age, body mass index (BMI), gender, race, family history of colorectal cancer, current smoking, history of previous polyps, physical activity, and aspirin use. Dietary intake of several nutrients was also evaluated for confounding and included measurements of vitamin D, dietary fat, fiber, folate, magnesium, calcium supplement use and total energy intake; in addition, we considered intake of red meat as a potential confounder. A confounding variable was included in the final analysis if it changed the point estimate by 10% or greater (23) and likelihood ratio tests comparing models with and without interaction terms were used to evaluate interactions by gender. We also assessed the possibility of heterogeneity of effect by treatment arm of the UDCA trial. We conducted stratified analyses by treatment arm of the association between 1,25D and adenoma recurrence and found no differences in the point estimate between intervention groups. We further assessed heterogeneity of effect between the two treatment groups by employing an interaction term for treatment arm and tertile of 1,25D and evaluating with a likelihood-ratio test; no heterogeneity was observed. The STATA statistical software package (version 9.0, Stata Corporation, College Station, TX) was used for data management and statistical analysis.

Results

Participant characteristics by tertile of 1,25(OH)₂D concentration are presented in Table 1. Overall, UDCA trial participants had a mean age of 66.1 ± 8.5 years, 94.6% reported White race, and 67.3% were male. Dietary intake included a mean energy intake of 1986.9 ± 819.9 kcal/d, calcium intake of 1007.0 ± 492.9 mg/d, and vitamin D intake of 136.2 ± 98.6 IU/d. On average, 71.9% of all participants reported regular use of supplements. Lower age and BMI, as well as fewer participants reporting a history of polyps or aspirin use, were observed in individuals in the highest tertile of 1,25(OH)₂D; however, only BMI, age, and gender were identified as confounding factors for inclusion on the logistic regression models.

There were no statistically significant associations between 1,25(OH)₂D and overall odds for metachronous adenoma (Table 2), with ORs (95% CIs) of 0.80 (0.60–1.07) and 0.81 (0.60–1.10) for participants in the second and third tertiles, respectively, compared to those in the lowest (p-trend=0.17). In addition, no statistically significant relationships were observed for multiplicity, large size, or villous histology. Heterogeneity of effect by gender was evaluated and no significant differences were observed. We also conducted exploratory analyses of associations between 1,25(OH)₂D concentrations and features of baseline adenomas. No statistically significant associations were identified (data not shown).

Odds of colorectal adenoma by anatomical location in the colon, proximal versus distal, were also evaluated (Table 3). There was an overall statistically significant association

between odds of proximal metachronous adenoma and tertile of circulating 1,25(OH)₂D, with ORs (95% CIs of 0.76 (0.56–1.04) for the second tertile and 0.71 (95% CI 0.52–0.98) for the third tertile, compared to the lowest (p-trend=0.04). No heterogeneity of effect by gender was observed for proximal adenomas. In contrast, a statistically significant interaction by gender (p=0.08) was found for distal adenomas. While there was no association observed between 1,25(OH)₂D and distal metachronous lesions among men, for women a statistically significant inverse trend (p=0.05) for reduced odds of distal metachronous adenoma was observed, with ORs (95% CIs) of 0.61 (0.33–1.15) and 0.53 (0.27–1.03) for the second and third tertiles compared to those in the lowest tertile. Overall, these results provide evidence for associations between circulating 1,25(OH)₂D concentration and odds of colorectal neoplasia that vary by gender and anatomical location in the colorectum.

Discussion

The results of the present study demonstrated that higher circulating 1,25(OH)₂D concentrations were not associated with odds for metachronous adenoma overall, nor with advanced features of adenomas. However, 1,25(OH)₂D was statistically significantly associated with reduced risk of proximal metachronous colorectal adenoma in our study population. We also found that the relationship between 1,25(OH)₂D and distal adenoma varied by gender, with significantly reduced odds among women with higher serum concentration of 1,25(OH)₂D, but not among men. The differences in associations between vitamin D metabolites and colorectal adenoma by anatomical location and gender have been suggested by previous work, as discussed below, though the epidemiological literature overall is relatively sparse for 1,25(OH)₂D.

The evidence to date for a relationship between serum 1,25(OH)₂D and risk of adenoma is equivocal. There are numerous studies that demonstrate a statistically significantly increased risk of colorectal neoplasia, including both adenomas and cancer, with lower circulating 25(OH)D concentration (5, 7, 24, 25). A prior analysis of UDCA trial participants by Jacobs et al. (8) revealed a suggestive but not statistically significant association between circulating 25(OH)D concentration and metachronous adenoma, with a stronger association in women compared to men. An expanded analysis of a pooled population including UDCA and Wheat Bran Fiber trial participants identified statistically significant associations between 25(OH)D levels and specific adenoma characteristics at baseline, but not with odds of metachronous adenoma (26). In the present study, we observed no associations between 1,25(OH)₂D and baseline adenomas (data not shown), but we did detect significant associations between this metabolite and metachronous proximal lesions, as well as distal metachronous adenoma in women. We can only speculate as to why 25(OH)D concentrations were associated with only baseline adenoma characteristics in this study population (26), while 1,25(OH)₂D levels were related only to some types of metachronous adenomas. One possibility is that the different vitamin D metabolites have actions in various stages of adenoma formation, such that the active hormonal form can prevent new growth of lesions, but does not inhibit the progression of lesions that have already been initiated. Another consideration regarding the study population is the potential role of the intervention agent, UDCA. Although the primary findings of the trial were null (18), Thompson et al.

conducted a further investigation of the role of gender on treatment effect in the UDCA trial (27). This study demonstrated that UDCA treatment was significantly associated with reduced odds of metachronous adenomas in men, but not women (28). However, no heterogeneity of effect for the association between $1,25(\text{OH})_2\text{D}$ and adenoma recurrence was observed by treatment arm in the present study, indicating that this was not a factor in the overall or gender-specific findings.

As with calcium, circulating $1,25(\text{OH})_2\text{D}$ concentrations are maintained within a tight homeostatic range due to their importance to multiple physiological functions (13, 29, 30). However, recent work by Skinner and Schwartz identified a statistically significant association between variation in serum calcium concentration and risk of fatal prostate cancer among the National Health and Nutrition Examination Survey (NHANES) participants (14). Furthermore, recent studies have shown that circulating $1,25(\text{OH})_2\text{D}$ concentrations are influenced by serum fibroblast growth factor 23 (FGF23) (15, 31–33). These studies indicate that circulating concentrations of homeostatically-controlled metabolites involved in the vitamin D endocrine system may exhibit enough variation to warrant study in an epidemiological setting. Prior epidemiological studies of $1,25(\text{OH})_2\text{D}$ and colorectal neoplasia have shown suggestive results.

In a population from the Nurses' Health Study (NHS), Platz et al. found that in 326 matched case and control pairs, participants with circulating $1,25(\text{OH})_2\text{D}$ in the lowest quartile demonstrated increased odds of distal colorectal adenoma (OR 1.58, 95% CI 1.03–2.40). There was also a non-significant trend of increased odds for women in the lower two quartiles of plasma $1,25(\text{OH})_2\text{D}$ (p-trend=0.20) (17). These results are similar to those of the current study, as we observed statistically significantly decreased odds of distal adenoma for women with higher circulating $1,25(\text{OH})_2\text{D}$ concentration (OR 0.53, 95% CI (0.27–1.03); p-trend=0.05). In contrast to these results, Lee et al. evaluated data from The Physician's Health Study and reported no significant association between $1,25(\text{OH})_2\text{D}$ concentration and colorectal cancer among men (6). An additional study by Feskanich et al., also of colorectal cancer, identified no statistically significant associations among NHS participants; however, they did observe that women in the highest quintile of $1,25(\text{OH})_2\text{D}$ concentration demonstrated increased odds of overall colorectal cancer (OR 1.77 95% CI 0.93–3.36) (16). The results for colorectal adenoma and cancer are conflicting, but indicate that any role of circulating $1,25(\text{OH})_2\text{D}$ in colorectal neoplasia may vary stage of carcinogenesis, gender, or colorectal sub-site. This concept is supported by the results of the present study, which identified statistically significant variations in the relationship between circulating $1,25(\text{OH})_2\text{D}$ and odds of metachronous adenomas by gender as well as by anatomical location. These findings support the hypothesis that colorectal neoplasia in specific anatomical areas of the GI tract may represent subtypes of the disease.

The proximal colon includes the transverse colon, hepatic flexure, ascending colon, and caecum; which are the areas proximal to the splenic flexure (34, 35), while the distal colon includes the areas distal to the splenic flexure with the descending colon, sigmoid colon, and rectum (34). These sub-sites of the colorectum have different embryonic origins, with the proximal colon originating from the midgut and the distal colorectum from the hindgut (34, 36). There are functional differences by sub-site that range from water and electrolyte

absorption to storage of feces, which may lead to unique carcinogenic exposures for cells in each region (35). This is supported by additional evidence that indicates differential carcinogenic pathways for distal versus proximal colorectal neoplasia (37). For example, microsatellite instability (MSI) is more frequently observed in proximal lesions compared to chromosomal instability in distal colon neoplasia (38, 39), while epigenetic methylation patterns also differ by region (40). Studies by Slattery et al. have found associations between tumors with MSI and vitamin D receptor (*VDR*) polymorphisms, such as FOKI, as well as evidence that the *VDR* polymorphisms are associated with proximal colorectal cancer (41, 42). Overall, it is possible that exposure of colonic epithelial cells to circulating 1,25(OH)₂D may have unique effects in the proximal colon versus the distal colon, particularly among men, due to differential factors promoting carcinogenesis, though further investigation is warranted.

The results of the current work also demonstrate reduced risk of both proximal and distal metachronous colorectal adenoma for women, though only the association with distal metachronous adenoma achieved statistical significance. Recent studies have demonstrated that men may be at increased risk for colorectal adenoma and recurrence (4, 43, 44); however, the evidence is more consistent for colorectal cancer (45, 46). An interaction between estrogen and vitamin D has been proposed to explain the observed reduced risk for risk of colorectal neoplasia in women (47, 48). Estrogen and vitamin D are both in the steroid hormone family and studies have proposed differences in estrogen receptor expression by colonic region (45, 49). Furthermore, Protiva et al. demonstrated that estrogen replacement therapy in postmenopausal women increased expression of the vitamin D receptor as well as genes related to the vitamin D endocrine system, including *CYP24A1* and E-cadherin (48). In turn, increased expression of E-cadherin inhibits the activity of the Wnt/β-catenin pathway, which acts to promote cell adhesion and differentiation (50, 51). Therefore estrogen and vitamin D may work synergistically to reduce activity of this cancer promotion pathway, which may help explain a more consistent overall association between 1,25(OH)₂D concentrations and adenoma recurrence among women in the present study.

The biological activity of vitamin D is initiated when 1,25(OH)₂D binds to the vitamin D receptor (30). At the cellular level, autocrine processing of 25(OH)D to 1,25(OH)₂D by intracellular 1α-hydroxylase (*CYP27B1*) is demonstrated in several tissues (52); however, there are many factors influencing this process. For example, variation in *CYP27B1* has been demonstrated to affect conversion of 25(OH)D to 1,25(OH)₂D (53). Furthermore, polymorphic variation in the Gc-globulin (GC), also known as the vitamin D binding protein, has been associated with circulating 25(OH)D and GC levels as well as concentrations of “free” versus GC-bound vitamin D metabolites (54, 55). Our own work has also demonstrated that Gc-globulin isotypes are associated with 25(OH)D and 1,25(OH)₂D availability to colon cancer cells (56). Therefore, it is of interest to determine which vitamin D metabolite is most reflective of tissue-level activity. While circulating 25(OH)D concentration is the most common measure of vitamin D status, it is known to be affected by a variety of factors including sun exposure, dietary intake, gender, physical activity levels, body size, and genetic variation (57, 58). However recent work has suggested that 1,25(OH)₂D may also be influenced by factors such as body size and season as well

(59). Recent literature suggests that 25(OH)D alone may not be a sufficient measure of vitamin D status (60); however, it is not clear if 1,25(OH)₂D would be a better marker or a potential biomarker to consider in combination with 25(OH)D and GC concentrations. The present work supports substantial future investigation of the potential for more complex assessment of vitamin D status.

The strengths of the present study include a large sample size, with over 1,000 participants, and prospective nature of the data, including measurements of metachronous adenoma among study participants. Furthermore, the data available for participants included comprehensive pathology of adenomas, circulating vitamin D metabolite concentrations, and complete demographic as well as dietary information. Limitations include that a single baseline measure of circulating 1,25(OH)₂D concentrations was available for each participant, and the population was largely White with an average age of approximately 65 years. Future studies in large, diverse populations with longitudinal measures of vitamin D metabolite concentrations will improve our understanding of the role of circulating 1,25(OH)₂D concentration in risk of colorectal neoplasia.

Conclusions

The results of the current study identify statistically significant associations between circulating 1,25(OH)₂D concentration and odds of colorectal metachronous adenoma that varies by anatomical location in the colon, as well as by gender. These findings add to a growing literature which suggests that variation in metabolites with homeostatically-controlled concentrations, such as 1,25(OH)₂D and calcium, may have a wide enough range to observe changes in risk of disease in some populations. It will be important to continue evaluating the role of 1,25(OH)₂D concentration in risk of colorectal adenoma and cancer in additional diverse populations in order to identify individuals at risk for disease and implement cancer prevention strategies.

Acknowledgments

This work was supported by the R25T training fellowship (R25CA078447) awarded to EH as well as a grant from the National Cancer Institute (R01CA140285) to EJ and PJ. EH was responsible for conducting the epidemiologic analysis and writing the manuscript. EJ, CS, PL, and PJ were responsible for assisting with manuscript preparation and editing as well as evaluating the analysis.

References

1. Haussler MR, Haussler CA, Bartik L, et al. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. *Nutr Rev*. 2008; 66:S98–S112. [PubMed: 18844852]
2. Jafri NS, Gould M, El-Serag HB, Duan Z, Davila JA. Incidence and survival of colorectal cancer among Hispanics in the United States: a population-based study. *Dig Dis Sci*. 2013; 58:2052–2060. [PubMed: 23086126]
3. Gawron AJ, Yadlapati R. Disparities in Endoscopy Use for Colorectal Cancer Screening in the United States. *Dig Dis Sci*. 2013 Mar; 59(3):530–537. 2014. [PubMed: 24248417]
4. Laiyemo AO, Doubeni C, Sanderson AK 2nd, et al. Likelihood of missed and recurrent adenomas in the proximal versus the distal colon. *Gastrointestinal endoscopy*. 2011; 74:253–261. [PubMed: 21549375]

5. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. *Int J Cancer*. 2011; 128:1414–1424. [PubMed: 20473927]
6. Lee JE, Li H, Chan AT, et al. Circulating Levels of Vitamin D and Colon and Rectal Cancer: The Physicians' Health Study and a Meta-analysis of Prospective Studies. *Cancer Prev Res (Phila)*. 2011; 4:735–743. [PubMed: 21430073]
7. Touvier M, Chan DS, Lau R, et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2011; 20:1003–1016. [PubMed: 21378269]
8. Jacobs ET, Alberts DS, Benuzillo J, Hollis BW, Thompson PA, Martinez ME. Serum 25(OH)D levels, dietary intake of vitamin D, colorectal adenoma recurrence. *J Steroid Biochem Mol Biol*. 2007; 103:752–756. [PubMed: 17223551]
9. Slaterry ML, Neuhausen SL, Hoffman M, et al. Dietary calcium, vitamin D, VDR genotypes and colorectal cancer. *Int J Cancer*. 2004; 111:750–756. [PubMed: 15252846]
10. Wei MY, Garland CF, Gorham ED, Mohr SB, Giovannucci E. Vitamin D and prevention of colorectal adenoma: a meta-analysis. *Cancer Epidemiol Biomarkers Prev*. 2008; 17:2958–2969. [PubMed: 18990737]
11. Zheng XE, Lipka S, Li T, et al. The relationship of vitamin D status, smoking, and colorectal adenoma: a retrospective study in an ethnically diverse community. *J Steroid Biochem Mol Biol*. 2013; 136:280–283. [PubMed: 23000288]
12. Bouillon R, Lieben L, Mathieu C, Verstuyf A, Carmeliet G. Vitamin D action: lessons from VDR and Cyp27b1 null mice. *Pediatric endocrinology reviews : PER*. 2013; 10(Suppl 2):354–366. [PubMed: 23858619]
13. Ryan JW, Anderson PH, Turner AG, Morris HA. Vitamin D activities and metabolic bone disease. *Clin Chim Acta*. 2013; 425C:148–152. [PubMed: 23911750]
14. Skinner HG, Schwartz GG. Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. *Cancer Epidemiol Biomarkers Prev*. 2008; 17:2302–2305. [PubMed: 18768497]
15. Jacobs E, Martinez ME, Buckmeier J, Lance P, May M, Jurutka P. Circulating fibroblast growth factor-23 is associated with increased risk for metachronous colorectal adenoma. *J Carcinog*. 2011; 10:3. [PubMed: 21383962]
16. Feskanich D, Ma J, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. *Cancer Epidemiol Biomarkers Prev*. 2004; 13:1502–1508. [PubMed: 15342452]
17. Platz EA, Hankinson SE, Hollis BW, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and adenomatous polyps of the distal colorectum. *Cancer Epidemiol Biomarkers Prev*. 2000; 9:1059–1065. [PubMed: 11045788]
18. Alberts DS, Martinez ME, Hess LM, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. *J Natl Cancer Inst*. 2005; 97:846–853. [PubMed: 15928305]
19. Ritenbaugh C, Aickin M, Taren D, et al. Use of a food frequency questionnaire to screen for dietary eligibility in a randomized cancer prevention phase III trial. *Cancer Epidemiol Biomarkers Prev*. 1997; 6:347–354. [PubMed: 9149895]
20. Egan JB, Thompson PA, Ashbeck EL, et al. Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence. *Cancer research*. 2010; 70:1496–1504. [PubMed: 20145122]
21. Hollis BW. Assessment of circulating 25(OH)D and 1,25(OH)2D: emergence as clinically important diagnostic tools. *Nutr Rev*. 2007; 65:S87–S90. [PubMed: 17867378]
22. Jacobs ET, Alberts DS, Foote JA, et al. Vitamin D insufficiency in southern Arizona. *Am J Clin Nutr*. 2008; 87:608–613. [PubMed: 18326598]
23. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. *American journal of epidemiology*. 1989; 129:125–137. [PubMed: 2910056]
24. Hong SN, Kim JH, Choe WH, et al. Circulating vitamin D and colorectal adenoma in asymptomatic average-risk individuals who underwent first screening colonoscopy: a case-control study. *Dig Dis Sci*. 2012; 57:753–763. [PubMed: 21984438]

25. Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011; 29:3775–3782. [PubMed: 21876081]
26. Jacobs ET, Hibler EA, Lance P, Sardo CL, Jurutka PW. Association between circulating concentrations of 25(OH)D and colorectal adenoma: a pooled analysis. *Int J Cancer*. 2013; 133:2980–2988. [PubMed: 23754630]
27. Thompson PA, Wertheim BC, Roe DJ, et al. Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. *Cancer Prev Res (Phila)*. 2009; 2:1023–1030. [PubMed: 19952360]
28. Thompson PA, Wertheim BC, Roe DJ, et al. Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. *Cancer Prev Res (Phila Pa)*. 2009; 2:1023–1030.
29. Moan J, Lagunova Z, Lindberg FA, Porojnicu AC. Seasonal variation of 1,25-dihydroxyvitamin D and its association with body mass index and age. *J Steroid Biochem Mol Biol*. 2009; 113:217–221. [PubMed: 19444938]
30. Dixon KM, Mason RS. Vitamin D. *Int J Biochem Cell Biol*. 2009; 41:982–985. [PubMed: 18723110]
31. Liu S, Gupta A, Quarles LD. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. *Curr Opin Nephrol Hypertens*. 2007; 16:329–335. [PubMed: 17565275]
32. Marsell R, Jonsson KB. The phosphate regulating hormone fibroblast growth factor-23. *Acta Physiol (Oxf)*. 2010; 200:97–106. [PubMed: 20618171]
33. Marsell R, Mirza MA, Mallmin H, et al. Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. *Osteoporos Int*. 2009; 20:1167–1173. [PubMed: 18974917]
34. Iacopetta B. Are there two sides to colorectal cancer? *Int J Cancer*. 2002; 101:403–408. [PubMed: 12216066]
35. Li FY, Lai MD. Colorectal cancer, one entity or three. *J Zhejiang Univ Sci B*. 2009; 10:219–229. [PubMed: 19283877]
36. Jacobs ET, Thompson PA, Martinez ME. Diet, gender, and colorectal neoplasia. *J Clin Gastroenterol*. 2007; 41:731–746. [PubMed: 17700421]
37. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. *Ann Intern Med*. 1990; 113:779–788. [PubMed: 2240880]
38. Albuquerque C, Baltazar C, Filipe B, et al. Colorectal cancers show distinct mutation spectra in members of the canonical WNT signaling pathway according to their anatomical location and type of genetic instability. *Genes, chromosomes & cancer*. 2010; 49:746–759. [PubMed: 20544848]
39. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. *Journal of surgical oncology*. 2004; 88:261–266. [PubMed: 15565587]
40. Koestler DC, Li J, Baron JA, et al. Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon. *Mod Pathol*. 2013 Jan; 27(1):145–155. 2014. [PubMed: 23868178]
41. Slatter ML, Yakumo K, Hoffman M, Neuhausen S. Variants of the VDR gene and risk of colon cancer (United States). *Cancer causes & control : CCC*. 2001; 12:359–364. [PubMed: 11456232]
42. Slattery ML, Wolff RK, Curtin K, et al. Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. *Mutation research*. 2009; 660:12–21. [PubMed: 18992263]
43. de Jonge V, Sint Nicolaas J, van Leerdam ME, Kuipers EJ, Veldhuyzen van Zanten SJ. Systematic literature review and pooled analyses of risk factors for finding adenomas at surveillance colonoscopy. *Endoscopy*. 2011; 43:560–572. [PubMed: 21437854]
44. Gao QY, Chen HM, Sheng JQ, et al. The first year follow-up after colorectal adenoma polypectomy is important: a multiple-center study in symptomatic hospital-based individuals in China. *Frontiers of medicine in China*. 2010; 4:436–442. [PubMed: 21128011]

45. Caldarella A, Crocetti E, Messerini L, Paci E. Trends in colorectal incidence by anatomic subsite from 1985 to 2005: a population-based study. *International journal of colorectal disease*. 2013; 28:637–641. [PubMed: 23478843]
46. Murphy G, Devesa SS, Cross AJ, Inskip PD, McGlynn KA, Cook MB. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. *Int J Cancer*. 2011; 128:1668–1675. [PubMed: 20503269]
47. Ding EL, Mehta S, Fawzi WW, Giovannucci EL. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial. *Int J Cancer*. 2008; 122:1690–1694. [PubMed: 18092326]
48. Protiva P, Cross HS, Hopkins ME, et al. Chemoprevention of colorectal neoplasia by estrogen: potential role of vitamin D activity. *Cancer Prev Res (Phila)*. 2009; 2:43–51. [PubMed: 19139017]
49. Papaxoinis K, Triantafyllou K, Sasco AJ, Nicolopoulou-Stamati P, Ladas SD. Subsite-specific differences of estrogen receptor beta expression in the normal colonic epithelium: implications for carcinogenesis and colorectal cancer epidemiology. *European journal of gastroenterology & hepatology*. 2010; 22:614–619. [PubMed: 20173645]
50. Egan JB, Thompson PA, Vitanov MV, et al. Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D receptor FokI polymorphism collectively modulate beta-catenin activity in colon cancer cells. *Molecular carcinogenesis*. 2010; 49:337–352. [PubMed: 20043299]
51. Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. *J Cell Biol*. 2001; 154:369–387. [PubMed: 11470825]
52. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. *Am J Clin Nutr*. 2008; 88:491S–499S. [PubMed: 18689389]
53. Jacobs ET, Van Pelt C, Forster RE, et al. CYP24A1 and CYP27B1 Polymorphisms Modulate Vitamin D Metabolism in Colon Cancer Cells. *Cancer research*. 2013; 73:2563–2573. [PubMed: 23423976]
54. Abbas S, Linseisen J, Slanger T, et al. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. *Cancer Epidemiol Biomarkers Prev*. 2008; 17:1339–1343. [PubMed: 18559548]
55. Lauridsen AL, Vestergaard P, Hermann AP, et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. *Calcif Tissue Int*. 2005; 77:15–22. [PubMed: 15868280]
56. Hibler EA, Jacobs ET, Dampf Stone A, Sardo CL, Galligan MA, Jurutka PW. Associations between vitamin D binding protein isotypes, circulating 25(OH)D levels, and vitamin D metabolite uptake in colon cancer cells. *Cancer Prev Res (Phila)*. 2014 Apr; 7(4):426–434. 2014. [PubMed: 24472850]
57. Hibler EA, Hu C, Jurutka PW, Martinez ME, Jacobs ET. Polymorphic variation in the GC and CASR genes and associations with vitamin D metabolite concentration and metachronous colorectal neoplasia. *Cancer Epidemiol Biomarkers Prev*. 2012; 21:368–375. [PubMed: 22144504]
58. Jacobs ET, Scragg R. Vitamin D and Health. *Complete Nutrition*. 2008; 3:7–9.
59. Lagunova Z, Porojnicu AC, Lindberg F, Hexeberg S, Moan J. The dependency of vitamin D status on body mass index, gender, age and season. *Anticancer research*. 2009; 29:3713–3720. [PubMed: 19667169]
60. Carter GD, Phinney KW. Assessing Vitamin D Status: Time For a Rethink? *Clin Chem*. 2014 [Epub ahead of print].

Table 1Baseline characteristics of participants, by tertile of 1,25(OH)₂D concentration.

Baseline Characteristics	Tertile of 1,25(OH) ₂ D Concentration (pg/ml) (mean ± sd)			
	All n = 1,151	22.7 ± 4.5 n=390	33.4 ± 2.8 n=379	47.0 ± 8.2 n=382
Age at baseline (mean ± sd)	66.1 ± 8.5	67.6 ± 7.9	66.1 ± 8.8	64.7 ± 8.5
BMI (kg/m ² , mean ± sd)	28.2 ± 4.8	29.0 ± 5.1	28.2 ± 4.6	27.3 ± 4.6
Male, n (%)	744 (67.3)	239 (61.3)	273 (72.0)	262 (68.6)
White, n (%)	1,070 (94.6)	362 (94.0)	355 (95.2)	353 (94.6)
Family History CRC, n (%) ¹	315 (27.4)	100 (25.6)	120 (31.7)	95 (24.9)
Current Smoker (yes), n (%)	134 (11.6)	42 (10.8)	47 (12.4)	45 (11.8)
Previous Polyps (yes), n (%) ^{2,3}	515 (44.7)	185 (47.4)	183 (48.3)	147 (38.5)
Aspirin Use (yes), n (%) ⁴	319 (27.7)	109 (28.0)	113 (29.8)	97 (25.4)
Dietary intake				
Energy (kcal/d)	1986.9 ± 819.9	1937.9 ± 818.8	2019.3 ± 829.8	2004.6 ± 810.9
Fat (g/d)	62.2 ± 32.0	60.8 ± 30.7	62.2 ± 32.7	63.7 ± 32.5
Fiber (g/d)	22.2 ± 10.7	22.2 ± 10.5	22.7 ± 10.9	21.8 ± 10.8
Vitamin D (IU/d)	136.2 ± 98.6	130.7 ± 96.8	144.1 ± 102.9	134.0 ± 96.0
Calcium (mg/d)	1007.0 ± 492.9	981.4 ± 472.7	1025.9 ± 482.8	1014.5 ± 522.2
Folate (mcg/d)	472.5 ± 235.2	459.7 ± 218.5	483.5 ± 237.0	474.7 ± 249.4
Magnesium (mg/d)	338.6 ± 136.3	332.4 ± 133.1	344.9 ± 138.0	338.5 ± 138.0
Supplement use (yes)	827 (71.9)	296 (75.9)	269 (71.0)	262 (68.6)

¹ Family history of colorectal cancer in one or more first degree relatives.² History of polyps prior to baseline.³ Number do not add up to 100% due to missing data.⁴ Aspirin use in the last month.

Adjusted odds ratios¹ (95% confidence intervals) for the association between 1,25(OH)₂D concentration and metachronous colorectal adenoma.

Table 2

Terile of 1,25(OH) ₂ D Concentration (pg/ml)	Metachronous Adenoma OR (95% CI) ¹					
	Any metachronous adenoma	Multiplicity (3 adenoma)	Large size (1 cm)	Villous histology ²		
	n (%)	OR (95% CI)	n (%)	OR (95% CI)	n (%)	OR (95% CI)
Pooled population						
T1 (22.7 ± 4.5)	181 (46.4)	1.00	42 (10.8)	1.00	36 (9.3)	1.00
T2 (33.4 ± 2.8)	154 (40.6)	0.80 (0.60–1.07)	29 (7.7)	0.74 (0.44–1.23)	25 (6.6)	0.74 (0.43–1.27)
T3 (47.0 ± 8.2)	150 (39.3)	0.81 (0.60–1.10)	28 (7.3)	0.80 (0.47–1.34)	29 (7.6)	0.90 (0.53–1.53)
p-trend		0.17		0.37		0.66
Men						
T1 (23.6 ± 4.5)	126 (47.9)	1.00	32 (12.2)	1.00	22 (8.4)	1.00
T2 (33.9 ± 2.6)	111 (43.9)	0.91 (0.64–1.29)	22 (8.7)	0.81 (0.45–1.46)	21 (8.3)	1.14 (0.60–2.16)
T3 (47.0 ± 7.6)	109 (42.3)	0.90 (0.63–1.30)	24 (9.3)	0.97 (0.54–1.75)	20 (7.8)	1.09 (0.56–2.12)
p-trend		0.58		0.90		0.79
Women						
T1 (21.1 ± 4.3)	54 (42.5)	1.00	10 (7.9)	1.00	12 (9.5)	1.00
T2 (32.2 ± 3.2)	43 (33.9)	0.68 (0.41–1.15)	7 (5.5)	0.67 (0.24–1.82)	5 (4.0)	0.38 (0.13–1.10)
T3 (47.2 ± 9.4)	42 (34.2)	0.76 (0.45–1.29)	4 (3.3)	0.46 (0.14–1.53)	10 (8.2)	0.91 (0.37–2.23)
p-trend		0.30		0.19		0.77
p-interaction ³		0.66		0.50		0.17

¹ Odds ratios adjusted for body mass index, gender (except for stratified analysis), and age.

² Villous histology was present if adenoma exhibited tubulovillous or villous histology (at least 25% villous).

³ P-interaction for gender and vitamin D status calculated using a likelihood ratio test.

Table 3

Adjusted odds ratios¹ (95% confidence intervals) for the association between 1,25(OH)₂D concentration and metachronous adenoma, by colorectal sub-site and gender.

Colorectal Sub-site OR (95% CI) ¹				
Tertile of 1,25(OH) ₂ D Concentration	Distal Adenoma		Proximal Adenoma	
	n (%)	OR (95% CI)	n (%)	OR (95% CI)
Pooled Population	96 (24.7)	1.00	142 (36.5)	1.00
T1 (22.7 ± 4.5)				
T2 (33.4 ± 2.8)	77 (20.4)	0.80 (0.56–1.13)	113 (30.0)	0.76 (0.56–1.04)
T3 (47.0 ± 8.2)	87 (22.8)	0.96 (0.68–1.36)	101 (26.5)	0.71 (0.52–0.98)
p-trend		0.82		0.04
Men				
T1 (23.6 ± 4.5)	64 (24.43)	1.00	104 (39.7)	1.00
T2 (33.9 ± 2.6)	57 (22.7)	1.00 (0.66–1.52)	79 (31.5)	0.76 (0.52–1.11)
T3 (47.0 ± 7.6)	69 (26.9)	1.32 (0.87–2.00)	73 (28.4)	0.72 (0.49–1.05)
p-trend		0.19		0.09
Women				
T1 (21.1 ± 4.3)	31 (24.4)	1.00	37 (29.1)	1.00
T2 (32.2 ± 3.2)	21 (16.5)	0.61 (0.33–1.15)	34 (26.8)	0.87 (0.49–1.52)
T3 (47.2 ± 9.4)	18 (14.6)	0.53 (0.27–1.03)	29 (23.6)	0.84 (0.47–1.51)
p-trend		0.05		0.56
p-interaction ²		0.08		0.27

¹ Odds ratios adjusted for body mass index, gender (except for stratified analysis), and age.

² P-interaction for gender and vitamin D status calculated using a likelihood ratio test.